Long-term survival after different first-line treatments for CLL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational follow-up of patients who received first-line therapy within the GCLLSG CLL13, CLL14, or CLL17 protocols, with overall survival (OS) from treatment start as the primary endpoint. The study collects information on subsequent therapy lines, comorbidities, genetic and serum markers, and other competing factors that might affect long-term survival. Data are gathered at participating centers and from consenting patients to create a pooled, standardized dataset enabling extended follow-up beyond what individual randomized trials can practically achieve. Collaborative sites across Germany and partner European groups contribute long-term outcome data to improve understanding of survival patterns after contemporary first-line CLL treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)

  * Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)
  * First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
  * Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
  * Subjects are willing and able to comply with procedures required in this protocol.

Exclusion Criteria:

* • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)

  * Subjects with legal incapacity
  * Subjects who are institutionalized by regulatory or court order
  * Subjects who are in dependence to the sponsor or the investigator

Where it's running

• University Hospital Cologne
  Cologne, Germany Recruiting
• Universitätsklinikum Ulm
  Ulm, Germany Recruiting

Study contacts

• Study coordinator: Kirsten Fischer, MD
• Email: kirsten.fischer@uk-koeln.de
• Phone: +4922147888220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Nemtabrutinib and venetoclax in untreated CLL/SLL

  This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07557056

• NX-5948 plus other medicines for B-cell cancers

  This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.

  Recruiting at 5 sites Phase 1/2 Nurix Therapeutics, Inc. · Aurora, Colorado and 8 other locations · NCT07520006

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.